دورية أكاديمية
أعرض في EDS

Oncogenic context shapes the fitness landscape of tumor suppression.

التفاصيل البيبلوغرافية
العنوان: Oncogenic context shapes the fitness landscape of tumor suppression.
المؤلفون: Blair LM; D2G Oncology, Mountain View, CA, USA., Juan JM; D2G Oncology, Mountain View, CA, USA., Sebastian L; D2G Oncology, Mountain View, CA, USA., Tran VB; D2G Oncology, Mountain View, CA, USA., Nie W; D2G Oncology, Mountain View, CA, USA., Wall GD; D2G Oncology, Mountain View, CA, USA., Gerceker M; D2G Oncology, Mountain View, CA, USA., Lai IK; D2G Oncology, Mountain View, CA, USA., Apilado EA; D2G Oncology, Mountain View, CA, USA., Grenot G; D2G Oncology, Mountain View, CA, USA., Amar D; D2G Oncology, Mountain View, CA, USA.; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.; Department of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA., Foggetti G; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Do Carmo M; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Ugur Z; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Deng D; Cellecta, Mountain View, CA, USA., Chenchik A; Cellecta, Mountain View, CA, USA., Paz Zafra M; Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Excellence Research Unit 'Modeling Nature' (MNat), University of Granada, E-18016, Granada, Spain.; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), E-18071, Granada, Spain., Dow LE; Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Politi K; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.; Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., MacQuitty JJ; D2G Oncology, Mountain View, CA, USA., Petrov DA; Department of Biology, Stanford University, Stanford, CA, USA.; Chan Zuckerberg BioHub, San Francisco, CA, USA., Winslow MM; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Rosen MJ; D2G Oncology, Mountain View, CA, USA. mike@d2g-oncology.com., Winters IP; D2G Oncology, Mountain View, CA, USA. ian@d2g-oncology.com.
المصدر: Nature communications [Nat Commun] 2023 Oct 12; Vol. 14 (1), pp. 6422. Date of Electronic Publication: 2023 Oct 12.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Proto-Oncogene Proteins p21(ras)*/genetics , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Mice ; Humans ; Animals ; Oncogenes/genetics ; Carcinogenesis/genetics ; Cell Transformation, Neoplastic/genetics ; Mutation
مستخلص: Tumors acquire alterations in oncogenes and tumor suppressor genes in an adaptive walk through the fitness landscape of tumorigenesis. However, the interactions between oncogenes and tumor suppressor genes that shape this landscape remain poorly resolved and cannot be revealed by human cancer genomics alone. Here, we use a multiplexed, autochthonous mouse platform to model and quantify the initiation and growth of more than one hundred genotypes of lung tumors across four oncogenic contexts: KRAS G12D, KRAS G12C, BRAF V600E, and EGFR L858R. We show that the fitness landscape is rugged-the effect of tumor suppressor inactivation often switches between beneficial and deleterious depending on the oncogenic context-and shows no evidence of diminishing-returns epistasis within variants of the same oncogene. These findings argue against a simple linear signaling relationship amongst these three oncogenes and imply a critical role for off-axis signaling in determining the fitness effects of inactivating tumor suppressors.
(© 2023. Springer Nature Limited.)
References: Mol Cancer Res. 2014 Jul;12(7):979-86. (PMID: 24770869)
Elife. 2019 Aug 27;8:. (PMID: 31452510)
Nat Protoc. 2009;4(7):1064-72. (PMID: 19561589)
Cancer Discov. 2020 Nov;10(11):1654-1671. (PMID: 32792368)
Genes Dev. 2007 Feb 15;21(4):379-84. (PMID: 17299132)
PLoS One. 2014 Apr 28;9(4):e95219. (PMID: 24777052)
Science. 2014 Jun 27;344(6191):1519-1522. (PMID: 24970088)
Yale J Biol Med. 2006 Dec;79(3-4):95-103. (PMID: 17940619)
Elife. 2021 Mar 29;10:. (PMID: 33779543)
Nat Rev Genet. 2018 Dec;19(12):741-755. (PMID: 30267031)
Chin J Cancer. 2013 Feb;32(2):63-70. (PMID: 22776234)
Clin Cancer Res. 2002 May;8(5):1178-84. (PMID: 12006535)
Cancer Res. 2021 Sep 1;81(17):4570-4580. (PMID: 34215621)
Exp Biol Med (Maywood). 2021 Jan;246(1):31-39. (PMID: 33019809)
Nat Methods. 2017 Jul;14(7):737-742. (PMID: 28530655)
Cell. 2019 May 30;177(6):1375-1383. (PMID: 31150618)
Cancer Discov. 2017 Aug;7(8):818-831. (PMID: 28572459)
Mol Cancer Res. 2015 Sep;13(9):1325-35. (PMID: 26037647)
Nat Genet. 2001 Dec;29(4):418-25. (PMID: 11694875)
Small GTPases. 2017 Jul 3;8(3):187-192. (PMID: 27416373)
Cancers (Basel). 2019 Aug 09;11(8):. (PMID: 31404976)
Nat Biotechnol. 2016 Feb;34(2):184-191. (PMID: 26780180)
Lab Anim Sci. 1999 Jun;49(3):319-23. (PMID: 10403450)
Cancer Res. 2015 Aug 1;75(15):3167-80. (PMID: 26001956)
Nature. 2014 Jul 31;511(7511):543-50. (PMID: 25079552)
Nat Biotechnol. 2003 Jun;21(6):635-7. (PMID: 12754523)
Cancer Res. 2012 Jun 15;72(12):3048-59. (PMID: 22511580)
Curr Drug Targets. 2014 Jan;15(1):65-79. (PMID: 24387334)
Nat Rev Cancer. 2020 Oct;20(10):573-593. (PMID: 32636489)
Cancers (Basel). 2019 Sep 17;11(9):. (PMID: 31533235)
Genes Dev. 2014 Mar 15;28(6):561-75. (PMID: 24589553)
Nat Rev Cancer. 2019 Sep;19(9):495-509. (PMID: 31406302)
N Engl J Med. 2002 Nov 14;347(20):1593-603. (PMID: 12432047)
Cancer Res. 2013 Nov 1;73(21):6448-61. (PMID: 24019382)
J Theor Biol. 1996 Oct 21;182(4):469-85. (PMID: 8944894)
Biochemistry (Mosc). 2000 Jan;65(1):2-27. (PMID: 10702637)
Elife. 2021 Aug 25;10:. (PMID: 34431477)
EMBO Mol Med. 2019 Jun;11(6):. (PMID: 31036704)
Nat Commun. 2017 Dec 12;8(1):2053. (PMID: 29233960)
Nat Rev Clin Oncol. 2010 May;7(5):251-65. (PMID: 20351699)
Mol Biol Evol. 2019 May 1;36(5):1008-1021. (PMID: 30903691)
Br J Cancer. 2010 Oct 12;103(8):1139-43. (PMID: 20877357)
Ann Oncol. 2022 Oct;33(10):1029-1040. (PMID: 35872166)
Cancer Discov. 2015 Aug;5(8):860-77. (PMID: 26069186)
Cancer Discov. 2012 Aug;2(8):685-93. (PMID: 22628411)
Cell. 2014 Oct 9;159(2):440-55. (PMID: 25263330)
Genes Dev. 2001 Dec 15;15(24):3243-8. (PMID: 11751630)
Cancer Discov. 2021 Jul;11(7):1736-1753. (PMID: 33707235)
Nat Genet. 2018 Apr;50(4):483-486. (PMID: 29610476)
Nucleic Acids Res. 2022 Jan 7;50(D1):D988-D995. (PMID: 34791404)
Cell. 2018 Feb 8;172(4):857-868.e15. (PMID: 29336889)
Oncogene. 2016 Mar 10;35(10):1328-33. (PMID: 26028035)
Cancer Discov. 2021 Jul;11(7):1754-1773. (PMID: 33608386)
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):. (PMID: 28148564)
Oncogene. 2020 Sep;39(38):6053-6070. (PMID: 32792685)
Elife. 2022 Sep 01;11:. (PMID: 36047771)
EMBO Mol Med. 2017 Feb;9(2):137-153. (PMID: 28028012)
Cell. 2018 Apr 5;173(2):321-337.e10. (PMID: 29625050)
Genes Dev. 2006 Jun 1;20(11):1496-510. (PMID: 16705038)
Cancer Res. 2015 Dec 15;75(24):5378-91. (PMID: 26567140)
PLoS Comput Biol. 2019 Apr 15;15(4):e1006953. (PMID: 30986244)
Nat Genet. 2009 May;41(5):544-52. (PMID: 19282848)
Genes Dev. 2015 Jul 15;29(14):1576-85. (PMID: 26178787)
Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. (PMID: 30045933)
معلومات مُعتمدة: R01 CA231253 United States CA NCI NIH HHS; R44 CA250672 United States CA NCI NIH HHS; R01 CA207133 United States CA NCI NIH HHS; R35 GM118165 United States GM NIGMS NIH HHS; R01 CA234349 United States CA NCI NIH HHS
المشرفين على المادة: EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
تواريخ الأحداث: Date Created: 20231012 Date Completed: 20231101 Latest Revision: 20240406
رمز التحديث: 20240406
مُعرف محوري في PubMed: PMC10570323
DOI: 10.1038/s41467-023-42156-y
PMID: 37828026
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-023-42156-y